InflaRx N.V.

InflaRx N.V. is a biopharmaceutical company focused on discovering and developing innovative therapies for inflammatory and autoimmune diseases. The company operates within the biotechnology sector, specializing in the development of novel antibodies that target the complement system, a crucial part of the immune system. InflaRx's research aims to address a range of conditions where uncontrolled complement activation plays a significant role, potentially leading to improved patient outcomes. By modulating the complement system, InflaRx seeks to provide therapeutic options for diseases with limited treatment alternatives. The company is committed to advancing its pipeline of drug candidates through clinical trials and regulatory approval processes, with the ultimate goal of bringing innovative medicines to patients in need.